Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis
Suman Gupta, Vanessa Yardley, Preeti Vishwakarma, et al.
Journal of Antimicrobial Chemotherapy (2014) Vol. 70, Iss. 2, pp. 518-527
Closed Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Nitro-Group-Containing Drugs
Kunal Nepali, Hsueh‐Yun Lee, Jing‐Ping Liou
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 6, pp. 2851-2893
Closed Access | Times Cited: 475
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Mark C. Field, David Horn, Alan H. Fairlamb, et al.
Nature Reviews Microbiology (2017) Vol. 15, Iss. 4, pp. 217-231
Open Access | Times Cited: 398
Chemotherapy of leishmaniasis: present challenges
Sílvia Reni Bortolin Uliana, Cristiana T. Trinconi, Adriano C. Coelho
Parasitology (2017) Vol. 145, Iss. 4, pp. 464-480
Open Access | Times Cited: 223
Recent updates and perspectives on leishmaniasis
Dianella Savoia
The Journal of Infection in Developing Countries (2015) Vol. 9, Iss. 06, pp. 588-596
Open Access | Times Cited: 179
Leishmaniasis drug discovery: recent progress and challenges in assay development
Bilal Zulfiqar, Todd Shelper, Vicky M. Avery
Drug Discovery Today (2017) Vol. 22, Iss. 10, pp. 1516-1531
Closed Access | Times Cited: 173
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases
Ang Chee Wei, Angie M. Jarrad, Matthew A. Cooper, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 18, pp. 7636-7657
Closed Access | Times Cited: 144
Nanostructured delivery systems with improved leishmanicidal activity: a critical review
Natascia Bruni, Barbara Stella, Leonardo Giraudo, et al.
International Journal of Nanomedicine (2017) Vol. Volume 12, pp. 5289-5311
Open Access | Times Cited: 101
Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art
Rebecca L. Charlton, Bartira Rossi‐Bergmann, Paul W. Denny, et al.
Parasitology (2017) Vol. 145, Iss. 2, pp. 219-236
Open Access | Times Cited: 99
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review
Soraya da Silva Santos, Renan Vinícius de Araújo, Jeanine Giarolla, et al.
International Journal of Antimicrobial Agents (2020) Vol. 55, Iss. 4, pp. 105906-105906
Closed Access | Times Cited: 95
Oxazole and isoxazole: From one-pot synthesis to medical applications
Ajay Thakur, Monika Verma, Ruchi Bharti, et al.
Tetrahedron (2022) Vol. 119, pp. 132813-132813
Closed Access | Times Cited: 52
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
Stephen Patterson, Susan Wyllie, Suzanne Norval, et al.
eLife (2016) Vol. 5
Open Access | Times Cited: 81
Nitroheterocyclic drug resistance mechanisms inTrypanosoma brucei
Susan Wyllie, Bernardo J. Foth, Anna Kelner, et al.
Journal of Antimicrobial Chemotherapy (2015) Vol. 71, Iss. 3, pp. 625-634
Open Access | Times Cited: 71
2-Amino-thiophene derivatives present antileishmanial activity mediated by apoptosis and immunomodulation in vitro
Klinger Antônio da França Rodrigues, Cínthia Nóbrega de Sousa Dias, Patrícia Néris Andrade, et al.
European Journal of Medicinal Chemistry (2015) Vol. 106, pp. 1-14
Closed Access | Times Cited: 67
Nitroaromatic Antibiotics as Nitrogen Oxide Sources
Allison M. Rice, Yueming Long, S. Bruce King
Biomolecules (2021) Vol. 11, Iss. 2, pp. 267-267
Open Access | Times Cited: 50
Current leishmaniasis drug discovery
Alessandra C. Pinheiro, M.V.N. De Souza
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 9, pp. 1029-1043
Open Access | Times Cited: 36
Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity
Charles E. Mowbray, Stéphanie Braillard, William C. Speed, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 24, pp. 9615-9624
Open Access | Times Cited: 59
Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis
Stephen Patterson, Alan H. Fairlamb
Current Medicinal Chemistry (2018) Vol. 26, Iss. 23, pp. 4454-4475
Open Access | Times Cited: 53
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis
Andrew M. Thompson, P. D. T. O’Connor, Andrew J. Marshall, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 10, pp. 4212-4233
Open Access | Times Cited: 52
Developing imidazole analogues as potential inhibitor forLeishmania donovanitrypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach
Rajan Kumar Pandey, Drista Sharma, Tarun Kumar Bhatt, et al.
Journal of Biomolecular Structure and Dynamics (2015) Vol. 33, Iss. 12, pp. 2541-2553
Closed Access | Times Cited: 50
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure–Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis
Andrew M. Thompson, P. D. T. O’Connor, Adrian Blaser, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 6, pp. 2530-2550
Open Access | Times Cited: 50
In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series
Magali Van den Kerkhof, Dorien Mabille, Eric Chatelain, et al.
International Journal for Parasitology Drugs and Drug Resistance (2018) Vol. 8, Iss. 1, pp. 81-86
Open Access | Times Cited: 48
Slow pace of antileishmanial drug development
Awanish Kumar, Satish Chandra Pandey, Mukesh Samant
Parasitology Open (2018) Vol. 4
Open Access | Times Cited: 48
Development of (6R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis
Andrew M. Thompson, P. D. T. O’Connor, Andrew J. Marshall, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 6, pp. 2329-2352
Open Access | Times Cited: 46
Functionalized Nitroimidazole Scaffold Construction and Their Pharmaceutical Applications: A 1950–2021 Comprehensive Overview
Ria Gupta, Sumit Sharma, Rohit Singh, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 561-561
Open Access | Times Cited: 20
Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates
Carlos García‐Estrada, Yolanda Pérez‐Pertejo, Bárbara Domínguez-Asenjo, et al.
Biomolecules (2023) Vol. 13, Iss. 4, pp. 637-637
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top